2025 Q3 -tulosraportti
41 päivää sittenTarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 118
Myynti
Määrä
627
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 409 | NON | AVA | ||
| 218 | NON | AVA | ||
| 150 | NON | NON | ||
| 197 | NON | NON | ||
| 1 817 | NON | NON |
Ylin
12VWAP
Alin
10,9VaihtoMäärä
0,9 76 326
VWAP
Ylin
12Alin
10,9VaihtoMäärä
0,9 76 326
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 999 | 2 500 | +4 499 | 0 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 53 199 | 62 186 | −8 987 | 46 467 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.
·1 t sittenWow, that is really a thorough piece of work you have done! Many thanks for it. I have rarely seen such a good analysis in here.
·1 päivä sitten · MuokattuJ.P. Morgan Healthcare Conference 2026 (January 12-15, 2026). The conference is strictly invitation-only, and J.P. Morgan does not publish a full agenda, participant list, or schedule. It is only available to invited clients. Over 8,000 participants are expected (executives, investors, analysts from pharma, biotech, medtech etc.), but no comprehensive overview is shared publicly. Danish Companies: Genmab: CEO Jan van de Winkel presents Tuesday, Jan. 13 at 3:45 PM PT (12:45 AM Danish time). Expect focus on their recent acquisition of Merus and their AI initiative. Zealand Pharma: CEO Adam Steensberg presents Monday, Jan. 12 (morning PT). They are one of the most anticipated participants due to their weight-loss pipeline (amylin analogues). Novo Nordisk: Although they rarely appear on the "official" public list early, Ludovic Helfgott (EVP) is confirmed for several panels, and the company holds extensive investor meetings concurrently. Ascendis Pharma: Confirmed as a participant in the main program with a focus on growth hormone and endocrinology data. CuraSight: Confirmed presence during JPM week to present their "uTRACE" and "uTREAT" technology. Global Pharma & Biotech (Main Program) Novartis (CEO Vas Narasimhan, Jan. 12 at 9:00 AM) Cytokinetics (CEO Robert I. Blum, Jan. 12 at 9:45 AM) Xenon Pharmaceuticals (CEO Ian Mortimer, Jan. 12 at 9:00-9:40 AM) Waystar Holding Corp. (CEO Matt Hawkins, Jan. 12 at 11:15 AM) Alcon (CEO David Endicott, Jan. 13 at 8:15 AM) Teva Pharma CEO Richard Francis Jan. 13 @ 08:15 Danaher (CEO Rainer M. Blair, Jan. 13 at 11:15 AM) Agios Pharmaceuticals (management, Jan. 14 at 8:15 AM) ICU Medical (management, Jan. 14 at 13:30 / 1:30 p.m. PT) Gilead Sciences Anna Asberg (SVP, IT & CIO) Confirmed Bristol Myers Squibb Wendy Bartie (EVP) Confirmed Eli Lilly Ruth Gimeno (Group VP) Confirmed Regeneron Boaz Hirshberg (SVP) Confirmed Arcus Biosciences Management Jan. 14 @ 15:00 Waystar CEO Matt Hawkins Jan. 12 @ 11:15 Henry Schein Management Confirmed Other companies that have announced participation: Moderna AstraZeneca Sanofi Inspire Medical Systems Tubulis ITM Agilent CuraSight More announcements typically come in the last days before and during the conference. Many smaller biotech companies are present in San Francisco during "JPM Week" for 1:1 meetings and side-events, without being on the official program.
·1 päivä sittenDoes Cessatech participate?
·1 päivä sittenThe JPM conference does not function as an open registration conference. One is invited and the invitation itself is a mark of quality. But of course not a guarantee for a specific result shortly thereafter.·1 päivä sitten · MuokattuCurasight also participated in the J.P Morgan conference in 2022, via a webcast. Perhaps this describes the difference very well: 2022: “Here is our technology and why it is interesting.” 2026: “Here is our progress in people, and here is what data actually moves risk.” They now have Phase I activated in uTREAT® and uTRACE is in Phase II (prostate) and there is continued clinical momentum in both uTREAT and uTRACE. They soon expect first meaningful data from dosimetry/safety in uTREAT, and partner-supply-infrastructure is in place for future development. Positive that they are now physically present at the event and ready with the pen 😉
·2 päivää sittenJust want to point out that all data presented at the conference must be made public before, meaning no later than Monday.·2 päivää sitten · MuokattuNo, not necessarily. Curasight may legally: • Share non-public clinical data with BD (Business Development) • Have NDA-protected dialogues • Discuss: o dosimetry o safety o platform o Phase II/III design • Receive feedback and interest from Big Pharma I.e., they can share initial dosimetry data (from FPD) under NDA They must not withhold decisions, agreements, or conclusive clinical results. The dividing line is: does it change the company's fundamental status? If the answer is no → no disclosure obligation. And preliminary read-out data for FPD is not of that caliber,- but it would be nice to hear some news from Andreas
·2 päivää sittenLike Nanexa: If it doesn't start a new rise within a couple of days, it's out of my portfolio. Get going! ....·1 päivä sittenHave read and pondered thoroughly, and changed my mind: have approx. doubled the position ....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
41 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.·1 t sittenWow, that is really a thorough piece of work you have done! Many thanks for it. I have rarely seen such a good analysis in here.
- ·1 päivä sitten · MuokattuJ.P. Morgan Healthcare Conference 2026 (January 12-15, 2026). The conference is strictly invitation-only, and J.P. Morgan does not publish a full agenda, participant list, or schedule. It is only available to invited clients. Over 8,000 participants are expected (executives, investors, analysts from pharma, biotech, medtech etc.), but no comprehensive overview is shared publicly. Danish Companies: Genmab: CEO Jan van de Winkel presents Tuesday, Jan. 13 at 3:45 PM PT (12:45 AM Danish time). Expect focus on their recent acquisition of Merus and their AI initiative. Zealand Pharma: CEO Adam Steensberg presents Monday, Jan. 12 (morning PT). They are one of the most anticipated participants due to their weight-loss pipeline (amylin analogues). Novo Nordisk: Although they rarely appear on the "official" public list early, Ludovic Helfgott (EVP) is confirmed for several panels, and the company holds extensive investor meetings concurrently. Ascendis Pharma: Confirmed as a participant in the main program with a focus on growth hormone and endocrinology data. CuraSight: Confirmed presence during JPM week to present their "uTRACE" and "uTREAT" technology. Global Pharma & Biotech (Main Program) Novartis (CEO Vas Narasimhan, Jan. 12 at 9:00 AM) Cytokinetics (CEO Robert I. Blum, Jan. 12 at 9:45 AM) Xenon Pharmaceuticals (CEO Ian Mortimer, Jan. 12 at 9:00-9:40 AM) Waystar Holding Corp. (CEO Matt Hawkins, Jan. 12 at 11:15 AM) Alcon (CEO David Endicott, Jan. 13 at 8:15 AM) Teva Pharma CEO Richard Francis Jan. 13 @ 08:15 Danaher (CEO Rainer M. Blair, Jan. 13 at 11:15 AM) Agios Pharmaceuticals (management, Jan. 14 at 8:15 AM) ICU Medical (management, Jan. 14 at 13:30 / 1:30 p.m. PT) Gilead Sciences Anna Asberg (SVP, IT & CIO) Confirmed Bristol Myers Squibb Wendy Bartie (EVP) Confirmed Eli Lilly Ruth Gimeno (Group VP) Confirmed Regeneron Boaz Hirshberg (SVP) Confirmed Arcus Biosciences Management Jan. 14 @ 15:00 Waystar CEO Matt Hawkins Jan. 12 @ 11:15 Henry Schein Management Confirmed Other companies that have announced participation: Moderna AstraZeneca Sanofi Inspire Medical Systems Tubulis ITM Agilent CuraSight More announcements typically come in the last days before and during the conference. Many smaller biotech companies are present in San Francisco during "JPM Week" for 1:1 meetings and side-events, without being on the official program.·1 päivä sittenDoes Cessatech participate?
- ·1 päivä sittenThe JPM conference does not function as an open registration conference. One is invited and the invitation itself is a mark of quality. But of course not a guarantee for a specific result shortly thereafter.·1 päivä sitten · MuokattuCurasight also participated in the J.P Morgan conference in 2022, via a webcast. Perhaps this describes the difference very well: 2022: “Here is our technology and why it is interesting.” 2026: “Here is our progress in people, and here is what data actually moves risk.” They now have Phase I activated in uTREAT® and uTRACE is in Phase II (prostate) and there is continued clinical momentum in both uTREAT and uTRACE. They soon expect first meaningful data from dosimetry/safety in uTREAT, and partner-supply-infrastructure is in place for future development. Positive that they are now physically present at the event and ready with the pen 😉
- ·2 päivää sittenJust want to point out that all data presented at the conference must be made public before, meaning no later than Monday.·2 päivää sitten · MuokattuNo, not necessarily. Curasight may legally: • Share non-public clinical data with BD (Business Development) • Have NDA-protected dialogues • Discuss: o dosimetry o safety o platform o Phase II/III design • Receive feedback and interest from Big Pharma I.e., they can share initial dosimetry data (from FPD) under NDA They must not withhold decisions, agreements, or conclusive clinical results. The dividing line is: does it change the company's fundamental status? If the answer is no → no disclosure obligation. And preliminary read-out data for FPD is not of that caliber,- but it would be nice to hear some news from Andreas
- ·2 päivää sittenLike Nanexa: If it doesn't start a new rise within a couple of days, it's out of my portfolio. Get going! ....·1 päivä sittenHave read and pondered thoroughly, and changed my mind: have approx. doubled the position ....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 118
Myynti
Määrä
627
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 409 | NON | AVA | ||
| 218 | NON | AVA | ||
| 150 | NON | NON | ||
| 197 | NON | NON | ||
| 1 817 | NON | NON |
Ylin
12VWAP
Alin
10,9VaihtoMäärä
0,9 76 326
VWAP
Ylin
12Alin
10,9VaihtoMäärä
0,9 76 326
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 999 | 2 500 | +4 499 | 0 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 53 199 | 62 186 | −8 987 | 46 467 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
41 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenAs I have previously mentioned, I have spent some time preparing a structured analysis of the Curasight case. The analysis is divided into two independent, but interconnected parts: 1. The Master - the analysis itself A data-driven review of Curasight as a theranostic platform, where the majority of the classic biotech risk has already been reduced, and where the remaining uncertainty is clearly defined, measurable, and time-limited. Link: https://drive.google.com/file/d/1BHjPJX6OBO3b4CHrbz8rOjnP7KEDkdjY/view?usp=drive_link 2. Appendix - evidence and decision basis A comprehensive reference and background material that documents historical behavior, market pricing, and Big Pharma logic – and explains why Curasight cannot be assessed with classic early-stage biotech logic. Link: https://drive.google.com/file/d/1kwC7DuYuYK9o3gn-pHSYVq3KR5hUat8A/view?usp=drive_link Together, this explains why I see Curasight as structurally different from many other biotech cases - and why I have chosen to have a more long-term perspective on my positions.·1 t sittenWow, that is really a thorough piece of work you have done! Many thanks for it. I have rarely seen such a good analysis in here.
- ·1 päivä sitten · MuokattuJ.P. Morgan Healthcare Conference 2026 (January 12-15, 2026). The conference is strictly invitation-only, and J.P. Morgan does not publish a full agenda, participant list, or schedule. It is only available to invited clients. Over 8,000 participants are expected (executives, investors, analysts from pharma, biotech, medtech etc.), but no comprehensive overview is shared publicly. Danish Companies: Genmab: CEO Jan van de Winkel presents Tuesday, Jan. 13 at 3:45 PM PT (12:45 AM Danish time). Expect focus on their recent acquisition of Merus and their AI initiative. Zealand Pharma: CEO Adam Steensberg presents Monday, Jan. 12 (morning PT). They are one of the most anticipated participants due to their weight-loss pipeline (amylin analogues). Novo Nordisk: Although they rarely appear on the "official" public list early, Ludovic Helfgott (EVP) is confirmed for several panels, and the company holds extensive investor meetings concurrently. Ascendis Pharma: Confirmed as a participant in the main program with a focus on growth hormone and endocrinology data. CuraSight: Confirmed presence during JPM week to present their "uTRACE" and "uTREAT" technology. Global Pharma & Biotech (Main Program) Novartis (CEO Vas Narasimhan, Jan. 12 at 9:00 AM) Cytokinetics (CEO Robert I. Blum, Jan. 12 at 9:45 AM) Xenon Pharmaceuticals (CEO Ian Mortimer, Jan. 12 at 9:00-9:40 AM) Waystar Holding Corp. (CEO Matt Hawkins, Jan. 12 at 11:15 AM) Alcon (CEO David Endicott, Jan. 13 at 8:15 AM) Teva Pharma CEO Richard Francis Jan. 13 @ 08:15 Danaher (CEO Rainer M. Blair, Jan. 13 at 11:15 AM) Agios Pharmaceuticals (management, Jan. 14 at 8:15 AM) ICU Medical (management, Jan. 14 at 13:30 / 1:30 p.m. PT) Gilead Sciences Anna Asberg (SVP, IT & CIO) Confirmed Bristol Myers Squibb Wendy Bartie (EVP) Confirmed Eli Lilly Ruth Gimeno (Group VP) Confirmed Regeneron Boaz Hirshberg (SVP) Confirmed Arcus Biosciences Management Jan. 14 @ 15:00 Waystar CEO Matt Hawkins Jan. 12 @ 11:15 Henry Schein Management Confirmed Other companies that have announced participation: Moderna AstraZeneca Sanofi Inspire Medical Systems Tubulis ITM Agilent CuraSight More announcements typically come in the last days before and during the conference. Many smaller biotech companies are present in San Francisco during "JPM Week" for 1:1 meetings and side-events, without being on the official program.·1 päivä sittenDoes Cessatech participate?
- ·1 päivä sittenThe JPM conference does not function as an open registration conference. One is invited and the invitation itself is a mark of quality. But of course not a guarantee for a specific result shortly thereafter.·1 päivä sitten · MuokattuCurasight also participated in the J.P Morgan conference in 2022, via a webcast. Perhaps this describes the difference very well: 2022: “Here is our technology and why it is interesting.” 2026: “Here is our progress in people, and here is what data actually moves risk.” They now have Phase I activated in uTREAT® and uTRACE is in Phase II (prostate) and there is continued clinical momentum in both uTREAT and uTRACE. They soon expect first meaningful data from dosimetry/safety in uTREAT, and partner-supply-infrastructure is in place for future development. Positive that they are now physically present at the event and ready with the pen 😉
- ·2 päivää sittenJust want to point out that all data presented at the conference must be made public before, meaning no later than Monday.·2 päivää sitten · MuokattuNo, not necessarily. Curasight may legally: • Share non-public clinical data with BD (Business Development) • Have NDA-protected dialogues • Discuss: o dosimetry o safety o platform o Phase II/III design • Receive feedback and interest from Big Pharma I.e., they can share initial dosimetry data (from FPD) under NDA They must not withhold decisions, agreements, or conclusive clinical results. The dividing line is: does it change the company's fundamental status? If the answer is no → no disclosure obligation. And preliminary read-out data for FPD is not of that caliber,- but it would be nice to hear some news from Andreas
- ·2 päivää sittenLike Nanexa: If it doesn't start a new rise within a couple of days, it's out of my portfolio. Get going! ....·1 päivä sittenHave read and pondered thoroughly, and changed my mind: have approx. doubled the position ....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
1 118
Myynti
Määrä
627
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 409 | NON | AVA | ||
| 218 | NON | AVA | ||
| 150 | NON | NON | ||
| 197 | NON | NON | ||
| 1 817 | NON | NON |
Ylin
12VWAP
Alin
10,9VaihtoMäärä
0,9 76 326
VWAP
Ylin
12Alin
10,9VaihtoMäärä
0,9 76 326
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 6 999 | 2 500 | +4 499 | 0 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 53 199 | 62 186 | −8 987 | 46 467 |
| Nordea Bank Abp | 1 381 | 1 599 | −218 | 140 |
| SSW Market Making GmbH | 8 232 | 8 319 | −87 | 0 |
| Svenska Handelsbanken AB | 790 | 450 | +340 | 0 |
| Skandinaviska Enskilda Banken AB | 690 | 280 | +410 | 280 |
| Avanza Bank AB | 5 035 | 992 | +4 043 | 33 |